ONCT vs. CMMB, BNOX, NHWK, HGEN, TNXP, ATHX, TFFP, NRSN, LSDI, and ZYNE
Should you be buying Oncternal Therapeutics stock or one of its competitors? The main competitors of Oncternal Therapeutics include Chemomab Therapeutics (CMMB), Bionomics (BNOX), NightHawk Biosciences (NHWK), Humanigen (HGEN), Tonix Pharmaceuticals (TNXP), Athersys (ATHX), TFF Pharmaceuticals (TFFP), NeuroSense Therapeutics (NRSN), Lucy Scientific Discovery (LSDI), and Zynerba Pharmaceuticals (ZYNE). These companies are all part of the "pharmaceutical preparations" industry.
Oncternal Therapeutics vs.
Oncternal Therapeutics (NASDAQ:ONCT) and Chemomab Therapeutics (NASDAQ:CMMB) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, community ranking, earnings and risk.
Oncternal Therapeutics has a beta of 1.54, suggesting that its stock price is 54% more volatile than the S&P 500. Comparatively, Chemomab Therapeutics has a beta of 0.35, suggesting that its stock price is 65% less volatile than the S&P 500.
Chemomab Therapeutics has lower revenue, but higher earnings than Oncternal Therapeutics. Chemomab Therapeutics is trading at a lower price-to-earnings ratio than Oncternal Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Oncternal Therapeutics had 1 more articles in the media than Chemomab Therapeutics. MarketBeat recorded 2 mentions for Oncternal Therapeutics and 1 mentions for Chemomab Therapeutics. Oncternal Therapeutics' average media sentiment score of 0.62 beat Chemomab Therapeutics' score of 0.33 indicating that Oncternal Therapeutics is being referred to more favorably in the media.
Oncternal Therapeutics received 13 more outperform votes than Chemomab Therapeutics when rated by MarketBeat users. However, 52.63% of users gave Chemomab Therapeutics an outperform vote while only 46.94% of users gave Oncternal Therapeutics an outperform vote.
16.7% of Oncternal Therapeutics shares are owned by institutional investors. Comparatively, 34.8% of Chemomab Therapeutics shares are owned by institutional investors. 8.0% of Oncternal Therapeutics shares are owned by insiders. Comparatively, 11.9% of Chemomab Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Chemomab Therapeutics has a net margin of 0.00% compared to Oncternal Therapeutics' net margin of -4,831.36%. Oncternal Therapeutics' return on equity of -71.49% beat Chemomab Therapeutics' return on equity.
Oncternal Therapeutics currently has a consensus target price of $5.77, indicating a potential upside of 1,784.53%. Chemomab Therapeutics has a consensus target price of $7.00, indicating a potential upside of 304.62%. Given Oncternal Therapeutics' higher possible upside, analysts plainly believe Oncternal Therapeutics is more favorable than Chemomab Therapeutics.
Summary
Oncternal Therapeutics beats Chemomab Therapeutics on 10 of the 15 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ONCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Oncternal Therapeutics Competitors List
Related Companies and Tools
